Last Updated : January 14, 2025
Details
Generic Name:
abemaciclib
Project Status:
Pending
Therapeutic Area:
HR-positive, HER2-negative advanced or metastatic breast cancer
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Verzenio
Project Line:
Reimbursement Review
Project Number:
PC0400-000
Call for patient/clinician input closed:
Tumour Type:
Breast
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
This reassessment request for reimbursement is with respect to the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy.
Submission Type:
Reassessment
Fee Schedule:
Pending
Indications:
Verzenio (abemaciclib) is indicated for the treatment of hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 14, 2025